Scisparc Ltd (SPRC)

$0.31 -0.01 (-2.62%)
Market Cap 3.60M
Revenue (ttm) 1.31M
Net Income (ttm) -6.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -479.39%
Debt to Equity Ratio 0.04
Volume 105,800
Avg Vol 2,501,642
Day's Range N/A - N/A
Shares Out 11.23M
Stochastic %K 25%
Beta 0.72
Analysts Strong Buy
Price Target $20.00

Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. It also sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufac...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 334 47180
Address:
Tower A, 2nd Floor 20 Raul Wallenberg Street, Tel Aviv, Israel
redbeamgold
redbeamgold Jun. 13 at 9:08 PM
$SPRC how does the war impact this stock
0 · Reply
shavitmi
shavitmi Jun. 10 at 4:16 PM
$SPRC merger play!!
0 · Reply
redbeamgold
redbeamgold Jun. 10 at 3:34 PM
$SPRC what’s the over/ under for merger finishing in September?
0 · Reply
DavidScott
DavidScott Jun. 2 at 3:15 AM
On watch tomorrow (swing trading) // Part 3 🔥📈📚 $SPRC $TOON $LVTX $PHUN $TROO
1 · Reply
ka1954
ka1954 May. 30 at 6:00 PM
$SPRC when is the RS? last time it was above $1 was in mid 2024. nasdaq will require an RS soon
2 · Reply
Orca_Bait
Orca_Bait May. 27 at 5:07 PM
$SPRC added sub .30
0 · Reply
MuesLee
MuesLee May. 20 at 5:45 PM
$SPRC they have more patents than anything else. Do something with these 175.234.000 patents :)
0 · Reply
Highriskstocks
Highriskstocks May. 13 at 12:44 PM
$SPRC
0 · Reply
noam825
noam825 May. 12 at 11:43 AM
$SPRC EL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the publication of a European patent application by the European Patent Office. The patent application relates to a combination treatment using Clearmind’s 5-methoxy-2-aminoindane (“MEAI”) and SciSparc’s Palmitoylethanolamide for the treatment of cocaine addiction.
0 · Reply
noam825
noam825 May. 12 at 11:42 AM
$SPRC newss! lets goo at open
0 · Reply
Latest News on SPRC
SciSparc Announces Publication of Japanese Patent Application

May 27, 2025, 7:32 AM EDT - 20 days ago

SciSparc Announces Publication of Japanese Patent Application

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Apr 25, 2025, 7:59 AM EDT - 7 weeks ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

CMND

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

Mar 3, 2025, 8:25 AM EST - 3 months ago

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

Feb 27, 2025, 8:45 AM EST - 3 months ago

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

Feb 18, 2025, 7:17 AM EST - 4 months ago

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Feb 4, 2025, 9:00 AM EST - 4 months ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 15, 2025, 7:34 AM EST - 5 months ago

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

Jan 13, 2025, 8:41 AM EST - 5 months ago

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Jan 7, 2025, 7:25 AM EST - 5 months ago

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

Jan 6, 2025, 11:04 AM EST - 5 months ago

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Jan 6, 2025, 7:50 AM EST - 5 months ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Dec 31, 2024, 9:24 AM EST - 5 months ago

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

S&P 500 Edges Lower, SciSparc Shares Surge

Dec 26, 2024, 2:36 PM EST - 6 months ago

S&P 500 Edges Lower, SciSparc Shares Surge

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Dec 26, 2024, 6:46 AM EST - 6 months ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

Dec 16, 2024, 7:40 AM EST - 6 months ago

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

Sep 30, 2024, 9:25 AM EDT - 9 months ago

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

Sep 26, 2024, 9:05 AM EDT - 9 months ago

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 23, 2024, 8:17 AM EDT - 9 months ago

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 18, 2024, 4:09 PM EDT - 9 months ago

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

Sep 16, 2024, 4:06 PM EDT - 9 months ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer

Sep 11, 2024, 7:40 AM EDT - 9 months ago

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Sep 6, 2024, 7:55 AM EDT - 10 months ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

Aug 29, 2024, 4:25 PM EDT - 10 months ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

Aug 28, 2024, 8:55 AM EDT - 10 months ago

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

Aug 23, 2024, 4:09 PM EDT - 10 months ago

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

Aug 22, 2024, 8:12 AM EDT - 10 months ago

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

Aug 19, 2024, 4:11 PM EDT - 10 months ago

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy

Aug 19, 2024, 7:51 AM EDT - 10 months ago

Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million

Aug 16, 2024, 4:30 PM EDT - 10 months ago

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million

SciSparc Updates Regarding the Status of the AutoMax Merger

Aug 14, 2024, 4:53 PM EDT - 10 months ago

SciSparc Updates Regarding the Status of the AutoMax Merger

SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

Aug 6, 2024, 8:57 AM EDT - 11 months ago

SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

Jul 22, 2024, 8:20 AM EDT - 11 months ago

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

Jul 17, 2024, 7:07 AM EDT - 11 months ago

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

Jul 16, 2024, 11:55 AM EDT - 11 months ago

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

Jul 16, 2024, 6:03 AM EDT - 11 months ago

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

Jul 8, 2024, 8:30 AM EDT - 1 year ago

SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company

SciSparc Secures Strategic Advantage with Grant of European Patent

May 31, 2024, 7:17 AM EDT - 1 year ago

SciSparc Secures Strategic Advantage with Grant of European Patent

Action Alliance Research: Family, Friends Need More Resources and Support to Help Loved Ones Who Are Struggling with Their Mental Health

May 21, 2024, 9:26 AM EDT - 1 year ago

Action Alliance Research: Family, Friends Need More Resources and Support to Help Loved Ones Who Are Struggling with Their Mental Health

SciSparc to Acquire AutoMax

Apr 11, 2024, 8:15 AM EDT - 1 year ago

SciSparc to Acquire AutoMax

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

Mar 27, 2024, 8:55 AM EDT - 1 year ago

SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression

SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research

Mar 21, 2024, 8:58 AM EDT - 1 year ago

SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research

SciSparc Granted Another Patent, Strengthening its Core Technology in Canada

Mar 18, 2024, 7:29 AM EDT - 1 year ago

SciSparc Granted Another Patent, Strengthening its Core Technology in Canada

SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial

Mar 14, 2024, 8:49 AM EDT - 1 year ago

SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial

SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure

Mar 12, 2024, 8:14 AM EDT - 1 year ago

SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure

SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder

Mar 8, 2024, 7:11 AM EST - 1 year ago

SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder

SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe

Mar 7, 2024, 7:49 AM EST - 1 year ago

SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe

SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology

Mar 6, 2024, 4:41 PM EST - 1 year ago

SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology

SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing

Feb 29, 2024, 8:35 AM EST - 1 year ago

SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

Feb 27, 2024, 7:58 AM EST - 1 year ago

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

Feb 20, 2024, 7:14 AM EST - 1 year ago

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

redbeamgold
redbeamgold Jun. 13 at 9:08 PM
$SPRC how does the war impact this stock
0 · Reply
shavitmi
shavitmi Jun. 10 at 4:16 PM
$SPRC merger play!!
0 · Reply
redbeamgold
redbeamgold Jun. 10 at 3:34 PM
$SPRC what’s the over/ under for merger finishing in September?
0 · Reply
DavidScott
DavidScott Jun. 2 at 3:15 AM
On watch tomorrow (swing trading) // Part 3 🔥📈📚 $SPRC $TOON $LVTX $PHUN $TROO
1 · Reply
ka1954
ka1954 May. 30 at 6:00 PM
$SPRC when is the RS? last time it was above $1 was in mid 2024. nasdaq will require an RS soon
2 · Reply
Orca_Bait
Orca_Bait May. 27 at 5:07 PM
$SPRC added sub .30
0 · Reply
MuesLee
MuesLee May. 20 at 5:45 PM
$SPRC they have more patents than anything else. Do something with these 175.234.000 patents :)
0 · Reply
Highriskstocks
Highriskstocks May. 13 at 12:44 PM
$SPRC
0 · Reply
noam825
noam825 May. 12 at 11:43 AM
$SPRC EL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the publication of a European patent application by the European Patent Office. The patent application relates to a combination treatment using Clearmind’s 5-methoxy-2-aminoindane (“MEAI”) and SciSparc’s Palmitoylethanolamide for the treatment of cocaine addiction.
0 · Reply
noam825
noam825 May. 12 at 11:42 AM
$SPRC newss! lets goo at open
0 · Reply
DavidScott
DavidScott May. 9 at 3:17 AM
On watch tomorrow (swing trading) // Part 2 🔥📈📚 $NNVC $SPRC $CAN $FFAI $BBAI
0 · Reply
JimmyCashMoney
JimmyCashMoney May. 8 at 6:17 PM
$NITO $NCNA is at bottom now, get in before the rip $SPRC
0 · Reply
LuckyBoy_PL
LuckyBoy_PL May. 8 at 2:42 PM
$SPRC
0 · Reply
rehak
rehak May. 8 at 2:34 PM
$SPRC someone can explain high rate for this stock?
0 · Reply
samba1008
samba1008 May. 8 at 1:02 PM
$SPRC I have a buy at .28 and sell at .40. Nothing fills..LOL
1 · Reply
redbeamgold
redbeamgold May. 8 at 12:41 AM
$SPRC so why did we have that run up and the mega volume???
1 · Reply
MadMaverick
MadMaverick May. 7 at 9:49 PM
⚡️WATCHLIST RECAP⚡️ ✅ $NCNA | +74% max profit ✅ $PLRZ | +9.5% max profit $SPRC did not hit entry.
0 · Reply
LuckyBoy_PL
LuckyBoy_PL May. 7 at 3:28 PM
$SPRC
0 · Reply
Pumpb0t
Pumpb0t May. 7 at 3:05 AM
$CAMP $JBDI $SPRC $BLMZ $AGMH
0 · Reply
Hero47
Hero47 May. 6 at 8:10 PM
$SPRC 
0 · Reply
FUTDATCHET
FUTDATCHET May. 6 at 3:54 PM
$SPRC= Great Surge⚡
0 · Reply
DarthGoat
DarthGoat May. 6 at 3:50 PM
$SPRC OOOUUUTTT +19% All calls in real time.
2 · Reply